Evidence map›Paper›PMID 26401039›Full record

ArticleJournal of virology2015

Vpr Enhances Tumor Necrosis Factor Production by HIV-1-Infected T Cells.

Ferdinand Roesch, Léa Richard, Réjane Rua, Françoise Porrot, Nicoletta Casartelli, Olivier Schwartz

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. The HIV-1Viruses · 2024
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. The HIV-1 Vpr Protein: A Multifaceted Target for Therapeutic Intervention.International journal of molecular sciences · 2017
    Review
  19. Article
  20. HIV-1 Vpr degrades the HLTF DNA translocase in T cells and macrophages.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Ferdinand RoeschInstitut Pasteur, Virus & Immunity Unit, Virology Department, Paris, France CNRS, URA3015, Paris, France Université Paris Diderot, Sorbonne Paris Cité, Cellule Pasteur, Paris, France.
Léa RichardInstitut Pasteur, Virus & Immunity Unit, Virology Department, Paris, France CNRS, URA3015, Paris, France Université Paris Diderot, Sorbonne Paris Cité, Cellule Pasteur, Paris, France.
Réjane RuaInstitut Pasteur, Virus & Immunity Unit, Virology Department, Paris, France CNRS, URA3015, Paris, France Université Paris Diderot, Sorbonne Paris Cité, Cellule Pasteur, Paris, France.
Françoise PorrotInstitut Pasteur, Virus & Immunity Unit, Virology Department, Paris, France CNRS, URA3015, Paris, France.
Nicoletta CasartelliInstitut Pasteur, Virus & Immunity Unit, Virology Department, Paris, France CNRS, URA3015, Paris, France.
Olivier SchwartzInstitut Pasteur, Virus & Immunity Unit, Virology Department, Paris, France CNRS, URA3015, Paris, France schwartz@pasteur.fr.
Centre National de la Recherche Scientifique · FRDélégation Paris 7 · FRInstitut Pasteur · FRSorbonne Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledThe HIV-1 accessory protein Vpr displays different activities potentially impacting viral replication, including the arrest of the cell cycle in the G2 phase and the stimulation of apoptosis and DNA damage response pathways. Vpr also modulates cytokine production by infected cells, but this property remains partly characterized. Here, we investigated the effect of Vpr on the production of the proinflammatory cytokine tumor necrosis factor (TNF). We report that Vpr significantly increases TNF secretion by infected lymphocytes. De novo production of Vpr is required for this effect. Vpr mutants known to be defective for G2 cell cycle arrest induce lower levels of TNF secretion, suggesting a link between these two functions. Silencing experiments and the use of chemical inhibitors further implicated the cellular proteins DDB1 and TAK1 in this activity of Vpr. TNF secreted by HIV-1-infected cells triggers NF-κB activity in bystander cells and allows viral reactivation in a model of latently infected cells. Thus, the stimulation of the proinflammatory pathway by Vpr may impact HIV-1 replication in vivo. IMPORTANCE: The role of the HIV-1 accessory protein Vpr remains only partially characterized. This protein is important for viral pathogenesis in infected individuals but is dispensable for viral replication in most cell culture systems. Some of the functions described for Vpr remain controversial. In particular, it remains unclear whether Vpr promotes or instead prevents proinflammatory and antiviral immune responses. In this report, we show that Vpr promotes the release of TNF, a proinflammatory cytokine associated with rapid disease progression. Using Vpr mutants or inhibiting selected cellular genes, we show that the cellular proteins DDB1 and TAK1 are involved in the release of TNF by HIV-infected cells. This report provides novel insights into how Vpr manipulates TNF production and helps clarify the role of Vpr in innate immune responses and inflammation.

Indexed as

Cell LineDNA-Binding ProteinsGene Expression RegulationHIV-1HumansMAP Kinase Kinase Kinase 7MAP Kinase Kinase KinasesNF-kappa BT-LymphocytesTumor Necrosis Factor-alphavpr Gene Products, Human Immunodeficiency VirusDDB1 protein, humanDNA-Binding ProteinsMAP Kinase Kinase Kinase 7MAP Kinase Kinase KinasesNF-kappa BTumor Necrosis Factor-alphavpr Gene Products, Human Immunodeficiency Virusvpr protein, Human immunodeficiency virus 1

Identifiers

PMID26401039
PMCPMC4645299
OpenAlexW1777570062

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.